We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Amyloid Precursor Protein Linked to Alzheimer's Disease Mitochondrial Damage

By LabMedica International staff writers
Posted on 19 Jul 2010
Mitochondrial dysfunction in neurons, which typifies Alzheimer's disease, may be at least partially due to the interaction of a mitochondrial protein with amyloid precursor protein (APP).

A paper published in the June 2010 issue of the European Journal of Neuroscience described the discovery of the link between AAP and the mitochondrial protein NIPSNAP1 (4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1).

First author Dr. More...
Hemachand Tummala, assistant professor of pharmaceutical sciences at South Dakota State University (Brookings, USA), explained, "In Alzheimer's disease, there is a protein involved called APP, amyloid precursor protein. If this protein is mutated, it causes early onset Alzheimer's disease. We do not know exactly what this protein does. One thing is very well documented in Alzheimer's disease; mitochondria in a cell are damaged. They lose their function. This happens long before the appearance of symptoms. So there is a theory that mitochondria play a big role in the disease progression.”

The authors reported that the interaction between APP and NIPSNAP1 was confirmed both in transiently transfected COS7 cells and in the mouse brain, where NIPSNAP1 is expressed at a high level. They demonstrated that NIPSNAP1 was targeted to the mitochondria via its N-terminal targeting sequence, and interacted with mitochondrial chaperone translocase of the outer membrane. Mitochondrial localization of NIPSNAP1 appeared to be critical for its interaction with APP, and overexpression of APP appeared to disrupt NIPSNAP1 mitochondrial localization.

"This work is still at the preliminary stages. If everything goes well, if we establish the link, this may in the future become a new therapeutic target,” said Dr. Tummala. "Our hypothesis is that mitochondria are damaged long before the appearance of symptoms. If you could stop that mitochondrial damage, it may slow down neuronal death and halt the disease progression. But that would be far in the future, not now.”

Related Links:
South Dakota State University






Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
HPV Test
Allplex HPV28 Detection
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.